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With the introduction of new drugs with different mechanisms of action, multiple myeloma (MM)
patients’ outcomes have improved. However, the efficacy seen in clinical trials is often not seen in
real-world settings and data on the effectiveness of MM therapies are needed. INSIGHT MM is a
prospective, global, non-interventional, observational study that is enrolling approximately 4200 pa-
tients with newly diagnosed or relapsed/refractory MM, making it the largest study of its kind to
date. The study aims to describe contemporary, real-world patterns of patient characteristics, clinical
disease presentation, therapies chosen, clinical outcomes (response, treatment duration, time-to-next-
therapy, progression-free and overall survival), safety, healthcare resource utilization and quality of
life. One interim analysis has been conducted to date; current accrual is approximately 3094 patients.
Trial registration number: NCT02761187
Lay abstract: Survival of patients with myeloma, a type of bone marrow cancer affecting the production
of healthy blood cells, has improved due to the development and approval of new treatments. Treatments
are approved based on clinical trials; however, limited data are available that confirm the effectiveness
of these same treatments in real-world routine clinical practice. INSIGHT MM is a large, global study that
will follow approximately 4200 myeloma patients from real-world settings for a minimum of 5 years,
describing their clinical characteristics, type of therapy received and their response to treatment, including
survival and toxicity. This review describes the study aims and methods.
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To describe contemporary, real-world patterns of patient characteristics, 
clinical disease presentation, therapeutic regimen chosen, and clinical outcomes
in multiple myeloma (MM) on a regional and global scale 
To evaluate the safety and effectiveness of current therapies, the impact of MM
on patients’ quality of life and healthcare resource utilization (HRU),
and the associations between patient characteristics, clinical disease presentation,
therapeutic patterns, and clinical outcomes
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Multiple myeloma (MM) is the second most common hematologic malignancy, with an estimated incidence of
30,770 new cases and 12,770 deaths in the USA in 2018 [1] and an estimated 48,300 new cases in Europe in
2018 [2]. Survival rates have improved dramatically over the past 20 years; the United States National Cancer
Institute Surveillance, Epidemiology, and End Results (SEER) Program estimated a 5-year relative survival of
29.3% for patients with MM who were diagnosed in 1990–1992, compared with 52.4% for those diagnosed in
2008–2014 [3]. In the UK, the estimated 5-year net survival for male and female patients diagnosed with MM
between 2011 and 2015, was 51.9% and 50.8%, respectively, compared with 22.4% and 21.9%, respectively, for
those diagnosed between 1990 and 1991 [4,5]. In a Swedish population-based study, the 5-year relative survival
rate improved from 0.28 to 0.41 for patients diagnosed with MM in 1973–1982 and 2003–2013, respectively [6].
Furthermore, MM is two- to three-fold more common in African Americans (AAs) compared with European
Americans and in AAs it is the most common hematologic malignancy, a disparity that may be due to a different
underlying genetic predisposition between these groups [7].
This improvement in outcomes for patients with MM has been attributed to the introduction of high-dose
chemotherapy plus autologous stem cell transplant, as well as the development, approval and use of multiple
new drugs and combination regimens in both the newly diagnosed MM (NDMM) and relapsed/refractory MM
(RRMM) settings [8]. Over the past 20 years, 12 therapies and agents with different mechanisms of action,
including immunomodulatory drugs, proteasome inhibitors (PIs), monoclonal antibodies (mAbs), as well as a
histone deacetylase (HDAC) inhibitor, a Bcl-2 inhibitor and a selective inhibitor of nuclear export (SINE) agent,
have been approved or have entered advanced phases of clinical testing, thus expanding the potential treatment
armamentarium against MM [8,9]. A list of key agents and regimens that are approved/recommended [10–12] or have
been/are being investigated in clinical trials is reported in Tables 1, 2 and Figure 1. This is not an exhaustive list
but provides an overview of the many agents and regimens available for MM treatment.
Mirroring the emergence of new therapies with different mechanisms of action, MM treatment strategies have
evolved, with more complex combination regimens being used, such as triplets versus doublets [13]. Additionally,
there is now an increased use of continuous or long-term maintenance therapy approaches, which have been shown
in clinical trials to prolong survival and delay disease progression, compared with fixed-duration or short-term
treatment plans [14].
As MM treatment options become more complex, choosing an appropriate agent or combination of agents
in routine clinical practice becomes increasingly challenging [15]. Although recommendations and guidelines for
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Table 1. Key agents and regimens that are approved/recommended for newly diagnosed multiple myeloma and
relapsed/refractory multiple myeloma.
Class Agent Initial approval NDMM regimens RRMM regimens
Proteasome inhibitors Bortezomib 2003 US FDA, 2004 EMA Vd, VCd, VTd, VRd, VMP, PAD V ± d, VCd, PAD, VTd, VRd,
Benda-Vd, V-Pom-d
Carfilzomib 2012 FDA, 2015 EMA KRd, KCd Kd, KRd, KCd, K-Pom-d
Ixazomib 2015 FDA, 2016 EMA IRd IRd, Id, I-Pom-d
Immunomodulatory drugs Thalidomide 2006 FDA, 2008 EMA Td, MPT, CTd, VTd, VTd-PACE VTd-PACE
Lenalidomide 2006 FDA, 2007 EMA Rd, MPR-R, CRd Rd, Benda-Rd, CRd
Pomalidomide 2013 FDA and EMA – Pom-d, Pom-Cd
Monoclonal antibodies Daratumumab 2015 FDA, 2016 EMA Dara-VMP Dara-Rd, Dara-Vd, Dara,
Dara-Pom-d
Elotuzumab 2015 FDA, 2016 EMA – Elo-Rd, Elo-Vd, Elo-Pom-d
Histone deacetylase inhibitors Panobinostat 2015 FDA and EMA – Pano-Vd, Pano-K, Pano-Rd
Table based on references [10–12,41].
Benda-Rd: Bendamustine, lenalidomide, dexamethasone; Benda-Vd: Bendamustine, bortezomib, dexamethasone; CRd: Cyclophosphamide, lenalidomide, dexamethasone;
CTd: Cyclophosphamide, thalidomide, dexamethasone; d: Dexamethasone; Dara: daratumumab; Dara-pom-d: Daratumumab, pomalidomide, dexamethasone; Dara-Rd: Dara-
tumumab, lenalidomide, dexamethasone; Dara-Vd: Daratumumab, bortezomib, dexamethasone; Dara-VMP: Daratumumab, bortezomib, melphalan, prednisone; Elo-Pom-d:
Elotuzumab, pomalidomide, dexamethasone; Elo-Rd: Elotuzumab, lenalidomide, dexamethasone; Elo-Vd: Elotuzumab, bortezomib, dexamethasone; EMA: European Medicines
Agency; FDA: Food and Drug Administration; Id: Ixazomib, dexamethasone; I-Pom-d: Ixazomib, pomalidomide, dexamethasone; IRd: Ixazomib, lenalidomide, dexamethasone;
KCd: Carfilzomib, cyclophosphamide, dexamethasone; Kd: Carfilzomib, lenalidomide; K-Pom-d: Carfilzomib, pomalidomide, dexamethasone; KRd: Carfilzomib, lenalidomide,
dexamethasone; MPR-R: Melphalan, prednisone, lenalidomide, plus lenalidomide maintenance; MPT: Melphalan, prednisone, thalidomide; NDMM: Newly diagnosed multiple
myeloma; PAD: Bortezomib, doxorubicin, dexamethasone; Pano-K: Panobinostat, carfilzomib; Pano-Rd: Panobinostat, lenalidomide, dexamethasone; Pano-Vd: Panobinostat,
bortezomib, dexamethasone; Pom-Cd: Pomalidomide, cyclophosphamide, dexamethasone; Pom-d: Pomalidomide, dexamethasone; Rd: Lenalidomide, dexamethasone; RRMM:
Relapsed/refractory multiple myeloma; Td: Thalidomide, dexamethasone; V: Bortezomib; VCd: Bortezomib, cyclophosphamide, dexamethasone; Vd: Bortezomib, dexametha-
sone; VMP: Bortezomib, melphalan, prednisone; V-Pom-d: Bortezomib, pomalidomide, dexamethasone; VRd: Bortezomib, lenalidomide, dexamethasone; VTd: Bortezomib,
thalidomide, dexamethasone; VTd-PACE: Bortezomib, thalidomide, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, etoposide.
Table 2. Agents and regimens that have been/are being investigated in clinical trials and are not yet approved for
multiple myeloma treatment.
Class Agent NDMM regimens RRMM regimens
Proteasome inhibitors Carfilzomib KMP (NCT01818752),
KCRd (NCT01554852)
KD once-weekly versus twice-weekly (NCT02412878)†
Ixazomib ITd (NCT03608501) ITd (NCT02410694)
Monoclonal antibodies Daratumumab Dara-Rd (NCT02252172),
Dara-RVd (NCT02874742),
Dara-VTd (NCT02541383)
Dara-Kd (NCT03158688)
Elotuzumab Elo-Rd (NCT01335399) Elo-Td (NCT01632150)
Isatuximab Isa-RVd (NCT03319667) Isa-Pom-d (NCT02990338),
Isa-Kd (NCT03275285)
BCL-2 inhibitor Venetoclax – Venetoclax-Vd, Venetoclax-Dara-Vd (NCT03701321)
SINE agent Selinexor – Selinexor-Vd (NCT03110562)
Checkpoint inhibitors Pembrolizumab Pembrolizumab-Rd (NCT02579863) Pembrolizumab-Rd (NCT02036502),
Pembrolizumab-Pom-d (NCT02576977)
Adoptive cell therapy Anti-CD19-CAR-T – Anti-CD19-CAR-T (NCT02135406)
Anti-CD138-CAR-T Anti-CD138-CAR-T (NCT01886976)
Anti-BCMA-CAR-T – Anti-BCMA-CAR-T (NCT02215967, NCT02658929,
NCT03090659, NCT02546167)
ADC Anti-BCMA-ADC – Anti-BCMA-ADC (NCT02064387)
BiTE Anti-BCMA/CD3-BiTE – Anti-BCMA/CD3-BiTE (NCT02514239)
Table based on references [9,42,43].
†Carfilzomib 20/70 mg/m2 administered once-weekly, carfilzomib 20/27 mg/m2 administered twice-weekly.
ADC: Antibody-drug conjugate; BCL-2: B-cell lymphoma 2; BCMA: B cell maturation antigen; BiTE: Bi-specfic T-cell engager; CAR-T: Chimeric antigen receptor T cells; CD: Clus-
ter of differentiation; Dara-Kd: Daratumumab, carfilzomib, dexamethasone; Dara-Rd: Daratumumab, lenalidomide, dexamethasone; Dara-RVd: Daratumumab, lenalidomide,
bortezomib, dexamethasone; Dara-Vd: Daratumumab, bortezomib, dexamethasone; Dara-VTd: Daratumumab, bortezomib, thalidomide, dexamethasone; Elo-Rd: Elotuzumab,
lenalidomide, dexamethasone; Elo-Td: Elotuzumab, thalidomide, dexamethasone; Isa-Kd: Isatuximab, carfilzomib, dexamethasone; Isa-Pom-d: Isatuximab, pomalidomide, dex-
amethasone; Isa-RVd: Isatuximab, lenalidomide, bortezomib, dexamethasone; ITd: Ixazomib, thalidomide, dexamethasone; KCRd: Carfilzomib, cyclophosphamide, lenalidomide,
dexamethasone; KD: Carfilzomib, dexamethasone; KMP: Carfilzomib, melphalan, prednisone; MM: Multiple myeloma; NDMM: Newly diagnosed MM; Pom-d: Pomalidomide,
dexamethasone; Rd: Lenalidomide, dexamethasone; RRMM: Relapsed/refractory MM; SINE: Selective inhibitor of nuclear export; Vd: Bortezomib, dexamethasone.
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Figure 1. Timeline of key agents and treatment combinations that are approved/recommended or have been investigated in Phase III
clinical trials in the (A) NDMM and (B) RRMM settings. Not all regimens or agents are approved or available in all countries.
Figure based on references [9–12,41,59] †Carfilzomib twice-weekly (20/27 mg/m2) versus once-weekly (20/70 mg/m2).
ASCT: Autologous stem cell transplant; CTd: Cyclophosphamide, thalidomide, dexamethasone; d: Dexamethasone; Dara: Daratumumab;
Dara-Rd: Daratumumab, lenalidomide, dexamethasone; Dara-Vd: Daratumumab, bortezomib, dexamethasone; Dara-VMP:
Daratumumab, bortezomib, melphalan, prednisone; Elo-Rd: Elotuzumab, lenalidomide, dexamethasone; EMA: European Medicines
Agency; EMN: European Myeloma Network; ESMO: European Society for Medical Oncology; FDA: Food and Drug Administration; IRd:
Ixazomib, lenalidomide, dexamethasone; K: Carfilzomib; Kd/D, carfilzomib, dexamethasone; KRd: Carfilzomib, lenalidomide,
dexamethasone; MPR-R: Melphalan, prednisone, lenalidomide, plus lenalidomide maintenance; MPT: Melphalan, prednisone,
thalidomide; NDMM: Newly diagnosed multiple myeloma; PAD: Bortezomib, doxorubicin, dexamethasone; Pano-VD: Panobinostat,
bortezomib, dexamethasone; Pom-d: Pomalidomide, dexamethasone; R: Lenalidomide; Rd: Lenalidomide, dexamethasone; RRMM:
Relapsed/refractory multiple myeloma; T: Thalidomide; Td: Thalidomide, dexamethasone; TE: Transplant-eligible; TiE:
Transplant-ineligible; US: United States; V: Bortezomib; VCD: Bortezomib, cyclophosphamide, dexamethasone; Vd: Bortezomib,
dexamethasone; VMP: Bortezomib, melphalan, prednisone; VMPT: Bortezomib, melphalan, prednisone, thalidomide; VRd: Bortezomib,
lenalidomide, dexamethasone; VT: Bortezomib, thalidomide; VTD: Bortezomib, thalidomide, dexamethasone.
treatment sequencing are available, these vary between countries and global regions [10,12], and different agents
and regimens are approved in different countries; as a result, there is currently no uniform, global standard-of-care
treatment for patients with MM, in either the NDMM or RRMM setting.
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Background & rationale
In this context, the availability of real-world data is increasingly important to our understanding of global varia-
tions in treatment practices and the impact of anti-MM therapies in the real-world setting. Despite the efficacy
improvements seen with anti-MM agents in the context of clinical trials, the same results are not always achieved
in the real-world setting in terms of the effectiveness of a regimen, with poorer long-term outcomes reported for
real-world patients versus clinical trial-enrolled patients [16,17]. This discrepancy is likely due to multiple factors,
including the rigorous study protocols followed in clinical trials [16] and the strict eligibility criteria used to select
patients for enrollment [18]. For example, of the patients enrolled in the CONNECT-MM registry, 40% were found
to be ineligible for inclusion in randomized controlled clinical trials (RCT) based on common exclusion criteria
(M-protein ≤1.0 g/dl, creatinine >2.5 mg/dl, low absolute neutrophil count [≤1.5 × 109/l] and low hemoglobin
[≤8 g/dl]) [19]. Importantly, RCT-ineligible patients had a significantly lower 3-year survival rate than RCT-eligible
patients (63% versus 70%; p < 0.05) [19], suggesting that clinical trial findings may not translate to the overall MM
population. In the CoMMpass registry, 22% of patients met the study definition of ineligibility for clinical trials [20].
A recent analysis estimated that only 25%, 35%, 41% and 47%, respectively, of USA real-world patients meet the
eligibility criterial of the ASPIRE (NCT01080391), TOURMALINE-MM1 (NCT01564537), ELOQUENT-2
(NCT01239797) and POLLUX (NCT02076009) RCTs, investigating lenalidomide/dexamethasone-based triplets
in RRMM [21]. Additionally, specific patient populations, such as elderly or frail patients, patients with comor-
bidities, advanced disease or aggressive and rapidly progressing disease, as well as some ethnic or racial minorities,
are typically under-represented in clinical trials [19,22,23], and their omission may therefore contribute to the gap
between efficacy and effectiveness. Other factors such as toxicities, the burden of long-term therapy, differences in
clinical care and practice patterns between treatment centers, as well as access to and cost of therapy in real-world
settings may also play a role in the observed gap between trial-based and real-world outcomes [16,24].
This gap between efficacy and effectiveness highlights the importance of collecting real-world data on MM
disease characteristics, treatment patterns and outcomes for anti-MM agents on a country-specific and global level
from unselected patient populations, to better inform treatment decisions in everyday clinical practice. Real-world
data for agents such as PIs, immunomodulatory drugs, mAbs and HDAC inhibitors are emerging in MM [17,25–29],
and a variety of methods have been used in the past approximately 10 years to collect and analyze real-world datasets,
including pharmaceutical company-sponsored prospective/retrospective registries and formal observational studies
(Table 3), as well as national registries, administrative claims studies and retrospective chart reviews [16].
Nevertheless, currently available data on clinical presentation, treatment patterns and outcomes for MM in the
community setting at a global level, as well as on patient-reported aspects such as health-related quality of life
(HRQoL), are limited. Therefore, additional real-world data are needed to bridge the gap between clinical trial
efficacy and routine clinical practice effectiveness of anti-MM agents and regimens, so that treating physicians
can effectively incorporate these new therapies into existing treatment algorithms and ultimately improve patient
outcomes [30].
INSIGHT MM study
Here we describe the design and rationale for the INSIGHT MM study (NCT02761187), a large, global, prospec-
tive, non-interventional, observational study of patients with NDMM or RRMM. This is the largest and the first
truly global study of its kind to date, incorporating multiyear enrollment and follow-up.
Objectives
INSIGHT MM is enrolling both NDMM and RRMM patients, and the primary objective of the study is to gain
a better understanding of patient and disease characteristics both at diagnosis and at relapse, treatment regimens
prescribed and associated patient outcomes in the real-world setting. Specific areas of interest include demographic
data, symptoms at presentation, disease characteristics at baseline and at relapse, and assessment of the impact of
MM and treatment on patients’ HRQoL and on healthcare resource utilization (HRU). Other objectives include:
assessment of patient outcomes based on cohort (NDMM or RRMM), type of treatment facility (academic versus
community, with academic centers being defined as those associated with a university or academic hospital), and
region or country of enrollment; evaluation of the treatment regimens used; assessment of the factors associated
with initiation or modification of treatment; evaluation of the associations between patient characteristics, clinical
disease presentation, therapeutic regimen chosen and clinical outcomes.
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Study design
INSIGHT MM is a non-interventional study and no study drug or medications are being provided. Patients are
to be treated according to the current standard of care at the study site and no changes in patients’ treatment
or management are required. Each patient’s care is determined entirely by his/her healthcare provider. However,
patients are required to complete patient self-reported outcomes (PRO) questionnaires during routine on-site clinic
visits. While participating in this study, patients can also be enrolled in another observational or non-blinded,
interventional study that does not prohibit participation in this trial. Eligible patients are being identified and
followed prospectively. Information on patient characteristics, diagnosis and previous treatment is collected from
hospital or clinic records at baseline; MM-specific disease management, safety and outcomes data are obtained
during routine on-site clinic visits on a quarterly basis.
A global steering committee has been established to provide support for the study, to advise on protocol
development, study conduct and activity, and to ensure that scientific validity and rigor are maintained throughout
the study. The steering committee comprises 20 treating physicians from around the globe (ten from the USA, ten
from elsewhere), who are considered experts in the field of MM treatment, as well as two patient representatives.
Inclusion of the two patient representatives ensures that the patients’ perspective is incorporated in every aspect of
the study, from study design and data collection, to the publication of the results and the communication of the
findings to the wider MM community; in addition, involvement of the patient representatives ensures that patients’
concerns and needs are considered throughout the conduct of the study.
The study is being conducted in accordance with local ethical guidelines, European directives on protection
of human patients in research, the Declaration of Helsinki, the European Network of Centres for Pharmacoepi-
demiology and Pharmacovigilance Guidelines, Good Pharmacoepidemiology Practice Guidelines and other local
or national specific, relevant guidelines, laws or regulations. All patients are required to provide written informed
consent before data collection, including authorization to use their patient medical records.
Eligibility criteria
The study is enrolling NDMM and RRMM patients of ≥18 years of age. Patients with NDMM must enroll within
3 months of treatment initiation. Patients with RRMM could have received up to three prior lines of therapy before
entering the study. All patients are required to have documented information available on the month and year of
diagnosis, criteria met for diagnosis, stage, including International Staging System (ISS) and revised-ISS (R-ISS),
prior therapies received, including duration of each prior line of treatment, whether they underwent stem cell
transplant and received consolidation/maintenance therapy and whether they received any investigational therapy.
In addition, all patients must be willing and able to complete the PRO instruments and sign the informed consent.
Patients are excluded from the study if they report to a study site only for a second opinion, if they are participating
in another trial that prohibits enrollment in this study or if they do not attend the clinic frequently enough to allow
for quarterly completion of the electronic case report forms (eCRFs).
Planned sample size, study period, & selection of study sites
The target enrollment for this study is approximately 4200 patients, with approximately equal numbers of NDMM
and RRMM patients to be enrolled. Patients are being enrolled over a period of approximately 3 years and will
be evaluated and followed-up prospectively for a minimum of 5 years, until death, withdrawal of consent or end
of study. The study is expected to end after all study patients have either completed a minimum of 5 years of
follow-up, have been lost to follow-up or have died prior to study end. Patients are followed-up longitudinally and
assessed on a quarterly basis to document changes in disease and/or lines of therapy.
Patients are being recruited from study sites around the world, including North America, South America,
Europe and Asia; 15 countries are participating (Figure 2). All participating sites are required to provide care for
MM patients and to appoint a healthcare provider who agrees to oversee the study conduct and ensure that the
protocol is followed correctly.
Variables, outcome measures & endpoints
Measures collected during the study include assessment of patient demographics and disease characteristics, in-
cluding presence of co-morbidities, disease symptoms at presentation, Eastern Cooperative Oncology Group
performance status, ISS or R-ISS disease stage and cytogenetic risk. Data on patients’ frailty status, including
Charlson comorbidity index, Katz index of independence in activities of daily living and Lawton instrumental
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Figure 2. INSIGHT MM: 15 participating countries.
activities of daily living scale, are also being collected, and may serve as an important predictor of outcomes and
toxicities. Details of therapeutic regimens received, including duration of each line of therapy and whether patients
have received prior stem cell transplant, are being collected and summarized. Outcome measures include overall
survival (OS), progression-free survival (PFS), response per International Myeloma Working Group criteria [31] and
time-to-next therapy (TTNT).
Table 4 lists variables collected during the study. These include documentation of treatment combinations
prescribed, duration of treatment, sequencing of therapies, retreatment and use of continuous versus fixed-duration
therapy, and if a patient has received therapy as part of a clinical trial. Patient outcomes including best response, OS,
PFS and TTNT, associated with treatment regimens are being documented prospectively from study entry. Changes
in treatment patterns over time are being documented by collecting information on initial and subsequent drug
regimens and classes received during the study for all patients, as they move through lines of therapy. In addition,
factors associated with treatment initiation and reasons for not receiving therapy are being collected. Modifications
to treatment, including reasons for changes to drug, dose, schedule and duration, are also being collected. The
impact of MM and treatment on patients’ HRQoL is being assessed through the use of validated PRO instruments,
and data on HRU are being collected. Safety is being investigated throughout the study by collecting information
on adverse events (AEs) and serious AEs leading to temporary or permanent treatment discontinuation or to drug
modifications, as well as by monitoring the frequency of second primary malignancies. Information on reasons for
dose modification and permanent drug discontinuation that are being collected include: AEs/toxicity, relapse due
to biochemical or clinical progression, remission or death, planned therapy change or patient/family preference.
Study assessments
Details of study assessments are reported in Table 4. Briefly, information on patient demographics, disease charac-
teristics and medical history prior to study inclusion, including prior anti-MM therapies received, is collected at
baseline. Disease management, effectiveness of treatment and safety are being assessed quarterly.
PROs are being collected at study inclusion and quarterly thereafter using paper forms during routine clinic
visits. HRQoL is being assessed based on:
• The Global Health Status/Quality of Life subscale from the European Organization for Research and Treatment
of Cancer (EORTC) Quality of Life Questionnaire – Core 30 module (QLQ–C30) [32];
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Table 4. Patient/outcome assessments and schedule.
Parameter Timing Assessment Prospective versus
retrospective
Patient demographics Baseline – Age
– Sex
– Race
– Ethnicity
– Height
– Weight
– Insurance information
– Geographic region
Prospective
Medical history at diagnosis Baseline – Date of initial diagnosis (month/year for RRMM; day/month/year for NDMM) and
criteria used (ISS, R-ISS)
– Stage (ISS or R-ISS)
– Cytogenetics/FISH risk†
– CRAB symptoms
– Hematology: white blood cell count, absolute neutrophil count, hemoglobin,
platelet count
– Chemistry: calcium, creatinine, alkaline phosphatase, total bilirubin, aspartate
aminotransferase, alanine aminotransferase, LDH, albumin, serum 2-microglobulin
and BUN‡
– SPEP, serum FLC† and UPEP†
– Imaging§
– History of MGUS/SMM
– Frailty status: CCI, Katz Index of Independence in activities of daily living and
Lawton instrumental activities of daily living scale
– ECOG performance status
NDMM patients:
prospective
RRMM patients:
retrospective
Medical history prior to study
inclusion
Baseline – Bone marrow
– FLC†
– M-component, immunofixation
– Imaging§
– GEP†
– Prodromal/other plasma cell disorders (MGUS, SMM, amyloidosis)
– Plasmacytoma and extramedullary disease
– Central nervous system involvement
– Stem cell transplant
– Vaccination
NDMM patients:
prospective
RRMM patients:
retrospective
Medical evaluation Baseline – CCI
– PN
– Pneumococcal vaccine
– Influenza A/B
– Hypertension requiring treatment
– Thromboembolism
– Cardiac left ventricular function
– Arrhythmias/pace-maker/AICD
– Osteopenia/osteoporosis
– Osteonecrosis of the jaw
– Cataracts
– MDS
– MM-related radiation therapy
– Orthopedic procedure/surgery for MM-related skeletal event
– Other surgery/procedures
Prospective
Quarterly – PN
– Amyloidosis
– Pneumonia
– Herpes zoster infection
– Hypertension
– Thromboembolism
– Cataracts
– Osteonecrosis of the jaw
– Skeletal-related events
– Cardiac events
Prospective
†Assessment was performed if the test was available and carried out as part of routine practice at the study sites.
‡ If available.
§ Includes assessment of evidence of plasmacytoma, extramedullary disease, and diffuse involvement.
¶Based on the latest version the National Cancer Institute the Common Terminology Criteria for Adverse Events.
AE: Adverse event; AICD: Automatic implantable cardioverter-defibrillator; BUN: Blood urea nitrogen; CCI: Charlson comorbidity index; CRAB: hyperCalcemia, Renal insufficiency,
Anemia, Bone lesions; ECOG: Eastern Cooperative Oncology Group; EORTC: European Organization for Research and Treatment of Cancer; FISH: Fluorescence in situ hybridization;
FLC: Free light chain; GEP: Gene expression profiling; HRU: Healthcare resource utilization; IMWG: International Myeloma Working Group; ISS: International Staging System; LDH:
Lactate dehydrogenase; MDS: Myelodysplastic syndrome; MGUS: Monoclonal gammopathy of undetermined significance; MM: Multiple myeloma; MRD: Minimal residual disease;
NDMM: Newly diagnosed multiple myeloma; NGS: Next-generation sequencing; PN: Peripheral neuropathy; PRO: Patient self-reported outcomes; QLQ-C30: Quality of Life Question-
naire – Core 30 Module; QLQ-MY-20: Quality of Life Questionnaire – 20-item Multiple Myeloma Module; QoL: Quality of life; R-ISS: Revised International Staging System; RRMM:
Relapsed/refractory multiple myeloma; SAE: Serious adverse event; SCT: Stem cell transplant; SMM: Smoldering multiple myeloma; SPEP: Serum protein electrophoresis; TSQM-9:
9-Item Treatment Satisfaction Questionnaire for Medication; UPEP: Urine protein electrophoresis.
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Table 4. Patient/outcome assessments and schedule (cont.).
Parameter Timing Assessment Prospective versus
retrospective
Yearly – Height and weight
– Vaccinations
– MDS
– Secondary primary malignancy
– Frailty status: CCI, Katz Index of Independence in activities of daily living and
Lawton instrumental activities of daily living scale
– ECOG performance status
Prospective
Prior therapies (RRMM) Baseline – RRMM: number of relapses and previous lines of therapy, regimens used in each
line, prior SCT or consolidation/maintenance therapy, use of investigational therapy
as part of a clinical trial, response, MRD†
Retrospective
Disease management Baseline and
quarterly
– Current therapy: type of regimens and drugs (including duration of treatment,
sequencing of therapies, retreatment and use of continuous versus fixed-duration
therapy), factors associated with treatment initiation, reasons for not receiving
therapy, response and MRD for each regimen,† SCT, supportive care
Prospective
Quarterly – Changes or modifications to treatment: drug, schedule, dose, line of therapy and
reasons for these changes
– Hematology and chemistry, safety, MM-related radiation therapy and
surgeries/procedures
Prospective
Effectiveness of treatment Quarterly – Bone marrow evaluation
– FISH and/or cytogenetics†
– MRD†
– Imaging§
– NGS and GEP†
– SPEP, serum FLC† and UPEP†
– Response per IMWG criteria [31]
– Progression status for each regimen
– Date and cause of death
Prospective
PROs Baseline and
quarterly
– EORTC QLQ-C30: two items on Global Health Status/QoL subscale
– EORTC QLQ-MY-20: single item on peripheral neuropathy
– TSQM-9: effectiveness, convenience and global satisfaction domains
Prospective
HRU Quarterly – Inpatient and intensive care admissions
– Reasons for admission and length of stay
– Outpatient clinic visits
– Emergency room visits
Prospective
Safety¶ Baseline and
quarterly
– AEs and SAEs leading to treatment discontinuation (temporary and permanent) or
drug modification
– Frequency of secondary primary malignancy
Prospective
†Assessment was performed if the test was available and carried out as part of routine practice at the study sites.
‡ If available.
§ Includes assessment of evidence of plasmacytoma, extramedullary disease, and diffuse involvement.
¶Based on the latest version the National Cancer Institute the Common Terminology Criteria for Adverse Events.
AE: Adverse event; AICD: Automatic implantable cardioverter-defibrillator; BUN: Blood urea nitrogen; CCI: Charlson comorbidity index; CRAB: hyperCalcemia, Renal insufficiency,
Anemia, Bone lesions; ECOG: Eastern Cooperative Oncology Group; EORTC: European Organization for Research and Treatment of Cancer; FISH: Fluorescence in situ hybridization;
FLC: Free light chain; GEP: Gene expression profiling; HRU: Healthcare resource utilization; IMWG: International Myeloma Working Group; ISS: International Staging System; LDH:
Lactate dehydrogenase; MDS: Myelodysplastic syndrome; MGUS: Monoclonal gammopathy of undetermined significance; MM: Multiple myeloma; MRD: Minimal residual disease;
NDMM: Newly diagnosed multiple myeloma; NGS: Next-generation sequencing; PN: Peripheral neuropathy; PRO: Patient self-reported outcomes; QLQ-C30: Quality of Life Question-
naire – Core 30 Module; QLQ-MY-20: Quality of Life Questionnaire – 20-item Multiple Myeloma Module; QoL: Quality of life; R-ISS: Revised International Staging System; RRMM:
Relapsed/refractory multiple myeloma; SAE: Serious adverse event; SCT: Stem cell transplant; SMM: Smoldering multiple myeloma; SPEP: Serum protein electrophoresis; TSQM-9:
9-Item Treatment Satisfaction Questionnaire for Medication; UPEP: Urine protein electrophoresis.
• A single item on peripheral neuropathy from the EORTC Quality of Life Questionnaire 20-item Multiple
Myeloma Module (QLQ-MY-20) [32];
• Nine items from the Treatment Satisfaction Questionnaire for Medication 9 (TSQM-9) covering the domains
of effectiveness, convenience and global satisfaction [33].
HRU is also assessed quarterly, including rates of inpatient and intensive care unit admissions, reasons for
admissions, length of stay, outpatient clinic visits and emergency room visits.
To ensure accuracy and completeness of the data, both an automatic query and a manual query process are
utilized. Automatic queries are intended to resolve insufficient data entries or missed fields. Manual queries are
conducted on flagged, new and changed data. Data reviews are conducted on a monthly basis at a minimum. In
addition, the study coordinator and principal healthcare provider at each participating site are responsible for the
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quality and consistency of data in the study and will maintain accurate electronic case report forms and patient
medical charts as part of the case histories.
Statistics
The planned sample size of approximately 4200 patients is intended to provide enough patients to characterize
treatment in a broad population, and to maintain a reasonable level of statistical power to detect differences between
subgroups. A sample size of 268 in each of any two comparison subgroups will have at least 80% power to detect a
difference between two proportions, given the true difference is at least 12%.
However, no formal hypothesis will be tested in this study and all analyses are exploratory in nature. All enrolled
patients are considered for inclusion in the analyses. Due to the observational nature of the study, and to address
potential confounding factors and bias, adjusted regression models will be used to determine the associations
between: (1) MM therapy regimens, disease attributes (e.g., disease stage and risk) and patient factors (e.g., age
and frailty) and (2) clinical outcomes, HRU and HRQoL. The final analysis will take place approximately 5 years
after enrollment of the last patient. Interim data summaries and formal interim analyses are being conducted as
appropriate while the study is ongoing, to understand patients’ initial clinical presentations at diagnosis and relapse
and the effectiveness of therapies in the real world [34,35].
Discussion
While clinical trial efficacy is critical for the MM treatment decision-making process, real-world data are becoming
increasingly important as they can inform clinicians about treatment effectiveness and toxicity in a broader patient
population treated outside of controlled clinical trials, with the ultimate goal of improving patients’ care and
outcomes. Numerous MM observational and national registry studies have been conducted or are ongoing/being
planned worldwide (Table 3 and Richardson et al. 2018 [16]), and evidence from these studies may help in
elucidating the critical factors contributing to the discrepancies reported between clinical trial efficacy and real-
world effectiveness as well as guiding treatment choices.
While data from several MM observational and national registry studies are already available (Table 3 and
Richardson et al. 2018 [16]), INSIGHT MM is the first non-interventional, observational study that is truly global
in nature, with patients being recruited from centers in 15 countries in North America, Central and South America,
Europe and Asia (Figure 2). Another unique aspect of this study is the open, collaborative nature of the project and
the willingness to share data beyond the investigators who participate in the trial, thereby providing a mechanism for
the submission of research ideas from the broader MM community. With an increasing number of real-world MM
registries being initiated in multiple geographical regions, the INSIGHT MM steering committee plans to explore
the power of collating datasets and conducting collaborative analyses with country-specific MM registries and other
observational studies, including the Czech Registry of Monoclonal Gammopathies [27,36] and the Australian and
New Zealand Myeloma and Related Diseases Registry [37]. Partnerships between registries will increase the power
of the analyses, provide a snapshot of MM treatment patterns and outcomes on a global scale, allow exploration of
a wider range of clinically relevant questions as well as provide results with higher accuracy and generalizability to
the whole MM population.
Inclusion of HRQoL endpoints in clinical trials can provide a more comprehensive evaluation of treatment
outcomes by incorporating the patient’s perspective. The collection of PRO data to evaluate patients’ HRQoL is
a particular strength of INSIGHT MM, highlighting the patient-centric approach taken in the development of
this study and the growing importance of PROs in real-world studies in MM (Table 3). In addition, several recent
pivotal Phase III trials of anti-MM agents have incorporated HRQoL analyses and demonstrated that HRQoL
benefits may be associated with improved outcomes [32,38,39]. Treatment-related factors, including toxicities, disease
symptoms and the burden of treatment and symptom/side-effect management, can negatively affect patients’
HRQoL [24]; therefore, it is particularly important to maintain HRQoL during MM therapy, especially for patients
receiving long-term/maintenance therapy. In the INSIGHT MM study, symptoms of peripheral neuropathy, one
of the most important complications of MM which can adversely impact on patients’ HRQoL [40], are reported by
patients through the EORTC QLQ-MY20 questionnaire. Additionally, patient satisfaction with their medication
and patients’ perspectives on treatment convenience will be assessed via the TSQM-9 questionnaire to provide
information on treatment adherence [33]; this is a critical challenge for patients receiving long-term/maintenance
treatment with agents requiring repeated dosing and frequent clinic visits, which can impose a substantial burden [24].
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Real-world data for anti-MM agents are already beginning to emerge [17,25–29] but, thanks to INSIGHT MM
and other registries, in the future these data will be much more extensive and robust as more patients are enrolled,
and it will become clearer which attributes, including which therapies, are having the greatest impact on patients’
outcomes and HRQoL.
Conclusion
Two data analyses of the INSIGHT MM study have been reported to date. The first included 1000 patients enrolled
from 13 countries (535 NDMM, 465 RRMM), and the second analysis included the first 1056 NDMM patients
enrolled from 14 countries [34,35]. Both analyses highlighted marked regional differences in real-world treatment
patterns in NDMM/RRMM, potentially due to differences in drug availability and treatment guidelines at academic
versus community centers [34,35]. Results from a second interim analysis, which will include approximately 3000
patients, are awaited with interest.
In conclusion, these interim data analyses and, ultimately, the final study findings will provide comprehensive
insights into patient and disease characteristics, treatment patterns, outcomes, patients’ HRQoL and safety of
contemporary treatment approaches for NDMM and RRMM patients in community and academic settings
worldwide. These data will be of substantial importance to the MM community, as they have the potential to
improve our understanding of the factors contributing to the discrepancies between clinical trial efficacy and
real-world effectiveness of anti-MM agents and regimens, and thereby improve patients’ outcomes.
Supplementary data
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Executive summary
Multiple myeloma
• Multiple myeloma (MM) patients’ survival has improved in the past 20 years, due to therapeutic advances,
including the introduction of new drugs and combination therapies and an increased use of
continuous/long-term therapy.
• The anti-MM treatment armamentarium is expanding, with new agents and more complex combinations being
added; in the absence of a global standard-of-care treatment for newly diagnosed MM (NDMM) or
relapsed/refractory MM (RRMM) patients, and given the incurable nature of MM, treating physicians are faced
with the challenge of choosing appropriate types and sequences of therapies for their patients in clinical practice.
Efficacy versus effectiveness
• While improved outcomes have been observed in clinical trials, emerging outcome data from observational
studies of real-world patients suggest a gap between clinical trial efficacy and real-world effectiveness.
• Factors contributing to this gap include: the stringent patient eligibility criteria used for clinical trial enrollment,
toxicity and treatment burden, treatment availability and access issues, as well as cost.
Real-world MM registries
• Real-world data on the use of anti-MM agents and regimens in routine clinical practice are emerging.
• Multiple MM observational and registry studies have been or are being conducted across the world; however,
current data on disease presentation, treatment patterns and outcomes at a global level are limited.
INSIGHT MM
• INSIGHT MM is the largest global, prospective, non-interventional, observational study conducted to date,
enrolling approximately 4200 patients with NDMM/RRMM from 15 countries worldwide.
Objectives
• To describe contemporary, real-world patterns of patient characteristics, clinical disease presentation, therapeutic
regimen chosen and clinical outcomes in MM on a regional and global scale.
• To evaluate the safety and effectiveness of current therapies, the impact of MM on patients’ health-related
quality of life (HRQoL) and healthcare resource utilization (HRU), and the associations between patient
characteristics, clinical disease presentation, therapeutic patterns and clinical outcomes.
Study design & eligibility criteria
• No study drugs are being provided and no changes in patients’ treatment management are required; patients are
being asked to complete patient self-reported outcomes (PRO) questionnaires.
• Eligible patients are adults with NDMM (within 3 months of starting treatment) or RRMM (1–3 prior therapies),
for whom information on time of diagnosis and current/prior therapies received is available to document each
patient’s longitudinal treatment course and associated outcomes.
Assessments
• Patient demographic, clinical disease presentation and medical history are collected at baseline; disease
management, treatment effectiveness, safety and HRU data are assessed quarterly.
• PROs are being used to assess HRQoL at baseline and quarterly based on the European Organization for Research
and Treatment of Cancer - Quality of Life Questionnaire – Core 30 module (EORTC QLQ-C30) and Quality of Life
Questionnaire 20-item Multiple Myeloma Module (QLQ-MY-20) (peripheral neuropathy) instruments and the
Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9) (effectiveness, convenience and global
satisfaction) questionnaire.
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